Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07591649 · ClinicalTrials.gov registry record · Phase 1
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07591649 is a Phase 1 study that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 18 participants.
The verdict
NCT07591649, a Phase 1 study, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG IL-2
- BIOLOGICAL AdaptNK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2035-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07591649
The ClinicalTrials.gov registry entry for NCT07591649 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07591649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07591649 about?
NCT07591649 is a clinical study titled "Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT". This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory ac...
What is the current status of trial NCT07591649?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-05-08. Estimated completion is 2035-03-01.
What interventions are being tested in trial NCT07591649?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), AdaptNK (BIOLOGICAL).
Who is sponsoring clinical trial NCT07591649?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.